After a few days and before the HIV results, a big pharma to announce "we have purchased X million shares of Inovio Pharmaceuticals in the open market, representing the 10% or 15% etc of this company's outstanding shares"?
The big order and all the recent buys makes me wonder....
With just Phase IIb results (which means the Phase III is being negotiated with FDA, EMEA or other regulatory) I do not think a buyout is at hand. With Phase IIb results that are going to get "expedited review" under the new regulations:
"Guidance for Industry
Expedited Programs for Serious Conditions––Drugs and Biologics
Which was just published this June, I think that a company might step in. But do not be surprised if it is a group interested in Hep C. This is the big payoff for the near future.
I'm asking if this is common in US markets and among bio companies, like it is in other markets, like in some in Europe and in Canada.
Usually such announcements are followed by negotiations between the purchaser and the company, sooner or later. In any case, the price appreciation is considerable for many reasons.